Dabigatran (Pradaxa) has received FDA approval for prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing hip replacement surgery, according to manufacturer Boehringer Ingelheim Pharmaceuticals.

The indication becomes the fourth to be approved for dabigatran, the firm noted. Previously, it was OK’d for reducing risk of stroke and systemic embolism in non-valvular atrial fibrillation patients, for treating DVT and PE in patients receiving parenteral anticoagulants, and to reduce risk of recurrent DVT and PE.